The FDA on April 17, 2020 approved TUKYSA® in combination with Trastuzumab and XELODA® (Capecitabine), for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. TUKYSA® is a product of Seattle Genetics, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
